2024 ACNM Annual Meeting
February 1-3, 2024
Hilton Orlando Lake Buena Vista
Orlando, FL

 

Each year, more than 500 attendees gather at the SNMMI Mid-Winter and ACNM Annual Meeting to collaborate with experts in the field, enhance their skills, and apply their newfound knowledge at their clinics. This event provides your company with an excellent chance to connect with leading professionals who are advancing precision medicine in an intimate setting.


ACNM offers multiple opportunities to earn online CME/SAM credits including webinars, MRI cases, and Scanner articles, as well as the ACNM Annual Meeting.

Learn more »  

Members enjoy many benefits including networking opportunities,  educational events, discounts and the latest information for improvement of clinical practice.

Learn More»  

 

ACNM works to represent members' interests through ongoing advocacy efforts, including monitoring regulatory actions affecting nuclear medicine issues.

Learn more »   

Residents are invited to become members of the ACNM Nuclear Medicine Residents Organization (NMRO) and gain free ACNM membership during their residency.

Learn More »  

Upcoming Webinars:

Prostate Radioligand Therapy
Date: March 12, 2024
Time: 12:00 pm EDT
Fee: Complimentary

CE credits pending, click below for more information.

NM Review Cases
Date: February 27, 2024
Time: 12:00 pm EDT
Fee: Complimentary

CE credits pending, click below for more information.



View all webinars »

ACNM 2023 Banquet Photos

ACNM News and Announcements

Pluvicto Prior to Taxane Therapy Prolongs rPFS

Results presented by Dr. Oliver Sartor on October 23 at the 2023 European Society for Medical Oncology (ESMO) Congress showed that:

  • The PSMAfore Phase 3 trial of 177Lu-PSMA-617 met its primary endpoint of radiographic progression-free survival (HR 0.41, 95% CI 0.29 to 0.56). Indeed, 177Lu-PSMA-617 more than doubled median radiographic progression-free survival to 12.0 months versus 5.6 months for change in androgen receptor pathway inhibitors (ARPIs).
  • 177Lu-PSMA-617 also showed improved (more than or equal 50%) decline in prostate-specific antigen, improved objective response rate, improved duration of response and improved quality of life compared to daily oral ARPI, along with improvements in other clinically meaningful efficacy endpoints.
  • PSMAfore continues to collect OS data.

These results show that in men with PSMA-positive metastatic castration-resistant prostate cancer who have progressed on prior ARPI, 177Lu-PSMA-617 prior to taxane therapy prolongs radiographic progression-free survival compared with change in ARPI.

A Few Useful Links regarding 177Lu-PSMA-617 therapy:

Guidelines on 177Lu-PSMA-617 therapy: https://tinyurl.com/ACNM177LuPSMA617

Consensus Statements/ Recommendations:
SNMMI: https://jnm.snmjournals.org/content/early/2023/06/08/jnumed.123.265952
ASCO: https://ascopubs.org/doi/abs/10.1200/JCO.22.01865?role=tab

2023 ACNM Board of Directors



ACNM NMRO Networking Event

NMRO networking event was held on Sunday, June 26, 2023, at 5:00 pm, CDT during the 2023 SNMMI Annual Meeting. Dr Bital Savir gave the introduction talk to the gathered residents and members. ACNM recognized the 2023 ACNM Resident/Fellow Research Award recipient, Dr. Bora Cengiz. There was an excellent presentation on topic   "Laying the Foundation Today for a Better Tomorrow” given by David Thyen, financial planner from the Larson company. Various investment plans available for residents were discussed in detail. Residents had a good networking time with each other along with enjoying the evening snacks.

                 

            


Official Publications

Members can access the following publications:

             

Our Vision

The American College of Nuclear Medicine (ACNM) is dedicated to providing education, training, and advocacy for the most sought-after and trusted experts in nuclear medicine who deliver state-of-the-art and innovative care and service to our patients and referring physicians.